IL1B and myocardial infarction: IL-1-targeted therapies have been shown to improve cardiovascular outcomes in clinical trials in patients with or at risk for acute myocardial infarction, heart failure, and recurrent pericarditis (Ridker and Everett, 2017; Grebe and Hoss, 2018; Abbate and Toldo, 2020).